ALSO NOTED: Guidant warns on defibrillators; FDA approves new Adderall use;and much more...

> Guidant said one of the recommendations it made to physicians in June designed to correct a problem with its recently recalled implantable defibrillators may actually increase risk to patients. Story

> Shire Pharmaceuticals received FDA approval to market Adderall to treat adolescents. Release

> Alpharma is expanding its warning on Kadian. Release

> Myogen has completed enrollment in its Phase III trial of ambrisentan. Release

And Finally... A new study shows a single dose of the anticancer drug carboplatin is as successful and less toxic than previous testicular cancer  treatments, and it is comparable to radiation in effectiveness. Story